Genmab & Seagen Present Preliminary Results of Tivdak (tisotumab vedotin) in P-II (innovaTV 207) Trial for Head & Neck Squamous Cell Carcinoma at ASTRO 2022
Shots:
- The P-II (innovaTV 207) trial evaluates tisotumab vedotin as monothx. in 532 patients with SCCHN who experienced disease progression & 1L Pt-containing regimen & checkpoint inhibitor
- The results showed a manageable safety profile & promising preliminary antitumor activity with the 1EPs of ORR (16%). The 2EPs included DCR, PFS/investigator (58.1%) & OS, m-PFS (4.2mos.) with a median follow-up (10.0mos.), m-OS (9.4mos.), AEs were consistent with the known safety profile of tisotumab vedotin
- Additionally, 67.7% of patients has grade ≥3 TEAEs, treatment-emergent SAEs & treatment-related SAEs (51.6% & 6.5%). The therapy has received accelerated approval for cervical cancer in Sept 2021
Ref: Globe Newswire | Image: Businesswire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com